New Jersey Medical School

Phoenix Children's Names New Chief of Neurosurgery

Retrieved on: 
Wednesday, April 24, 2024
UCLA, Health system, Lead, University, Mayo Clinic, Bangladesh Technical Education Board, Hospital, Neuropsychology, General surgery, News, Neuroscience, MD, Doctor of Philosophy, Research, New Jersey Medical School, Barrow Neurological Institute, Spine, Editorial, Neurology, Neurosurgery, Child, Epilepsy, Neoplasm, Seattle Children's, Rehabilitation, Research institute, Growth, Nursing

PHOENIX, April 24, 2024 /PRNewswire/ -- Phoenix Children's, one of the nation's fastest-growing pediatric health systems, today announced the hire of accomplished surgeon-scientist Jason Scott Hauptman, MD, PhD, as division chief of neurosurgery, part of Barrow Neurological Institute at Phoenix Children's. His appointment is part of a broader effort to hire top clinical and research leadership in high-demand specialty areas as Phoenix Children's solidifies its position as the premier pediatric health system in the Southwest.

Key Points: 
  • "Patient families will benefit from Dr. Hauptman's epilepsy surgery expertise, and our health system will benefit from his impressive track record in medical education, mentorship, research and academia," said Daniel Ostlie, MD, surgeon in chief at Phoenix Children's.
  • As division chief of neurosurgery at Phoenix Children's , Dr. Hauptman will provide strategic direction and administrative leadership while also collaborating with multidisciplinary teams to provide top-quality clinical care for children with neurological conditions.
  • He will also hold academic appointments with Mayo Clinic Arizona, Creighton University School of Medicine and the University of Arizona College of Medicine — Phoenix.
  • Phoenix Children's is consistently recognized as one of U.S. News & World Report's " Best Children's Hospitals " for neurology and neurosurgery.

One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Constellation, Single-cell analysis, Lung cancer, EGFR, Health, Biotechnology, Rachel Haurwitz, New Jersey Medical School, Foundation Medicine, Cornell University, University, Knowledge, American Cancer Society, Research, Esperion Therapeutics, Cancer, A.I, Medicine, Summit Health, Esperies, Therapy, Drug development, Partner, MorphoSys, JPMorgan Chase, Thomas Jefferson University Hospital

to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.

Key Points: 
  • to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors.
  • Our proprietary discovery engine has identified its first promising targets, and we are preparing to start drug development activities in 2025.
  • Bolstering our Board with such seasoned leaders will be a key factor to success.”
    Dr. Scott Braunstein brings over 30 years of knowledge and experience gained in the biotechnology, pharmaceutical, and biotech portfolio management industries.
  • Dr. Braunstein is currently on the board at Trevena and Caribou Biosciences.

RWJBarnabas Health and Rutgers Health to Showcase Breakthrough Cardiology Data at the American College of Cardiology Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
CMR, TME, FACC, National Health Interview Survey, Research, Obesity, Hypertension, MRI, Cooperman Barnabas Medical Center, Facial muscles, HIV, Diabetes, Risk, National Health, Patient, Stroke, RWJBarnabas Health, Community Medical Center, Mortality, Aortic stenosis, American College of Cardiology, Telehealth, Faculty, New Jersey Medical School, NHIS, Abstract, American College, Smoking, LVDD, Rutgers University, Division, TAVR, Collection, Jersey City Medical Center, ACC, YPLL, Acute coronary syndrome, Health, Meta-analysis, Dietary supplement

WEST ORANGE, N.J., March 25, 2024 /PRNewswire/ -- Physician-scientists from RWJBarnabas Health and Rutgers Health will present an extensive portfolio of innovative cardiovascular data from their clinical research program at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Atlanta, Georgia on April 6 to 8, 2024. A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.

Key Points: 
  • A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.
  • RWJBarnabas Health cardiac centers of excellence are nationally recognized for patient care and superior outcomes, including being named as one of Becker's top 100 Great Heart Programs in the country and recognized by American College of Cardiology as a Proven Quality Program.
  • Prior studies suggest that distinct patient subgroups with aortic stenosis may experience left ventricular systolic and diastolic dysfunction before the development of severe AS.
  • The study included patients who had received an angiogram done within 14 days of the CMR.

Knock Out Opioid Abuse Day Learning Series Returns in 2024

Retrieved on: 
Wednesday, January 24, 2024
Drug, University, Addiction, Advertising, Partnership, Emergency medicine, Fentanyl, Emergency medical services, American Academy, Government, Communication, Public, Heroin, COVID-19, CME, New Jersey Medical School, Organization, Law enforcement, Prohibition

Millburn, NJ, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Partnership for a Drug-Free New Jersey (PDFNJ), the Office of the New Jersey Coordinator for Addiction Responses and Enforcement Strategies (NJ CARES) and the Opioid Education Foundation of America (OEFA) have renewed their partnership in 2024 and will once again host the Knock Out Opioid Abuse Day Learning Series.

Key Points: 
  • Millburn, NJ, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Partnership for a Drug-Free New Jersey (PDFNJ), the Office of the New Jersey Coordinator for Addiction Responses and Enforcement Strategies (NJ CARES) and the Opioid Education Foundation of America (OEFA) have renewed their partnership in 2024 and will once again host the Knock Out Opioid Abuse Day Learning Series.
  • Over the course of 11 webinars from January to December 2024, the series will offer the public more insight and information into the multi-faceted components of the opioid epidemic in New Jersey and around the nation.
  • The series is a branch of PDFNJ’s Knock Out Opioid Abuse Day statewide initiative, which has been held annually on October 6 since 2016 to educate residents and prescribers on the risks of prescription opioids and to raise awareness of the opioid crisis throughout the state.
  • To learn more about Knock Out Opioid Abuse Day and for a schedule of webinars, please visit knockoutday.drugfreenj.org .

ENT and Allergy Associates, LLP Strengthens Commitment to Excellence Welcomes Otolaryngologist Guy Talmor, M.D. to West Nyack, NY Office

Retrieved on: 
Thursday, December 21, 2023
Otorhinolaryngology, Neck, Restaurant, Research, LLP, Nose, Rutgers University, Head, Medicine, University, New Jersey Medical School, ENT, Gold, Patient, Physiology, Life, Nursing

With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.

Key Points: 
  • With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.
  • Dr. Talmor earned his Bachelor of Science degree in physiology and neuroscience from the University of California at San Diego.
  • He went on to receive his medical degree from the prestigious Keck School of Medicine of University of Southern California, graduating summa cum laude.
  • Dr. Talmor will complete his ENT residency at Rutgers New Jersey Medical School in June 2024.

NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System

Retrieved on: 
Monday, December 11, 2023
RF, Food, DSM-IV codes, EDEN, New Jersey Medical School, NMTC, Epilepsy, FDA, Perseverance, Patient safety, Neurosurgery, Brain, MD, Doctor of Philosophy, Temperature, Calendar, Patient, Stereoelectroencephalography, Food and Drug Administration, Medical device

EDEN PRAIRIE, Minn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance to market its OneRF™ Ablation System for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures.

Key Points: 
  • This may also reduce hospital stays, number of surgeries, and adverse events, while offering significant benefits from a clinical perspective.
  • The addition of temperature control at the point of ablation also may enhance patient safety.
  • The OneRF Ablation System is the Company’s first device with a therapeutic indication and its third FDA 510(k)-cleared device.
  • NeuroOne estimates the current brain ablation market to be at least $100M worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs.

ENT and Allergy Associates, LLP Continues to Add Talented Physicians Welcomes Otolaryngologist Monica Christine Azmy, M.D. to its Old Bridge, NJ Office

Retrieved on: 
Monday, November 13, 2023
New Jersey Medical School, Volleyball, LLP, American Academy, Gold, CCC, Boston College, Patient, Harry, Otorhinolaryngology, D.O, Montefiore Medical Center, Rutgers University, Friends, Family, Montefiore, Nursing, Dentistry, Science, Biology

To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.

Key Points: 
  • To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.
  • This continues with Monica Christine Azmy, M.D., who is the latest recruit to join the group's 240+ board-certified physicians.
  • Dr. Azmy will begin seeing patients at ENTA’s Old Bridge, NJ office effective October 1, 2024.
  • To learn more about ENTA, find a local office or book an appointment, visit www.entandallergy.com or call 1-855-ENTA-DOC.

MBrace Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Antibody Drug Conjugate at 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 7, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, MMAE, MBrace, Safety, Research and development, New Jersey Medical School, Spacecraft, Therapy, Annexin A5, Immunoglobulin G, ADC, HED, Breast cancer, Teaching hospital, Patient, TNBC, Division, Laboratory, Breast, Cancer, Professor, Cell, Cooper University Hospital, HR, Medical imaging

MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.

Key Points: 
  • MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.
  • In the data presented today, robust and selective EphA5 expression was detected in greater than 80% of triple negative breast cancer (TNBC) and greater than 80% of HR+ breast cancer tissue samples.
  • EphA5 expression was not detected in adjacent, non-malignant breast tissue or normal breast.
  • Details of the poster presentation are as follows:
    Presenter: Fernanda Staquicini, Ph.D., Director of Research & Development, MBrace Therapeutics

Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants

Retrieved on: 
Wednesday, November 1, 2023
Rheumatology, Science, Research, Sarcoidosis, Education, Health, Washington University in St. Louis, Family, Rational ignorance, Critical care, New Jersey Medical School, Critical Care Medicine (journal), FSR, Division, Clinical trial, Hospital, Overalls, Patient, Health system, Associate, Pharmaceutical industry, Nursing, Rutgers University

FSR is dedicated to advancing the needs of all patients impacted with sarcoidosis and to closing the health care disparities gap that affects our community.

Key Points: 
  • FSR is dedicated to advancing the needs of all patients impacted with sarcoidosis and to closing the health care disparities gap that affects our community.
  • These capacity building grant recipients completed a competitive application process and have been awarded a complimentary 1-year membership (valued at $5,000) in the FSR-GSCA.
  • “Washington University is honored to become a member of the FSR Global Sarcoidosis Clinical Alliance.
  • "FSR is honored to have these three prestigious institutions join our extraordinary group of FSR Global Sarcoidosis Clinic Alliance members.

Page and Davis Brody Bond Join Forces Expanding New York City Presence

Retrieved on: 
Thursday, November 2, 2023
Interior Design, Engineering, Architecture, Manufacturing, Commercial Building & Real Estate, Construction & Property, Building Systems, National Park Service, New Jersey Medical School, FAIA, United States Commercial Service, LEED, 2021 occupation of the United States embassy compound in Yemen, Congress, Diplomatic mission, 1979 U.S. embassy burning in Islamabad, World Trade Center, History of the National Park Service, National September 11 Memorial & Museum, Republic, AIA, Davis Brody Bond, USAID, Library, African Americans, LEED AP, ASEAN, U.S. Department of Agriculture Cotton Annex, McIntyre Medical Sciences Building, Interior design, Pharmaceutical industry

Page , a leading multidisciplinary design, architecture, and engineering firm, today announced that Davis Brody Bond has joined its team to expand its presence in New York City.

Key Points: 
  • Page , a leading multidisciplinary design, architecture, and engineering firm, today announced that Davis Brody Bond has joined its team to expand its presence in New York City.
  • “For several years, we’ve been thoughtfully assessing the best way to extend our presence into New York City, and given our past collaboration with Davis Brody Bond, we knew the firm shared our design ethos and client-first approach.
  • Davis Brody Bond partners -- Steven Davis, FAIA, Will Paxson, AIA, LEED, Carl Krebs, FAIA, and Christopher Grabé, FAIA LEED-- will become principals at Page.
  • All of Davis Brody Bond’s employees will also be joining Page.